<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50864">Thiazolidinediones</z:chebi> (TZDs) are synthetic <z:chebi fb="4" ids="48705">agonists</z:chebi> of the ligand-activated transcription factor peroxisome proliferator-activated receptor-gamma (PPARgamma) </plain></SENT>
<SENT sid="1" pm="."><plain>TZDs are known to curtail <z:mp ids='MP_0001845'>inflammation</z:mp> associated with peripheral organ <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>As <z:mp ids='MP_0001845'>inflammation</z:mp> precipitates the neuronal <z:hpo ids='HP_0011420'>death</z:hpo> after <z:hpo ids='HP_0001297'>stroke</z:hpo>, we tested the efficacy of TZDs in preventing brain damage following transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) in adult rodents </plain></SENT>
<SENT sid="3" pm="."><plain>As <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:mp ids='MP_0002055'>diabetes</z:mp> complicate the <z:hpo ids='HP_0001297'>stroke</z:hpo> outcome, we also evaluated the efficacy of TZDs in hypertensive rats and type-2 diabetic mice subjected to transient MCAO </plain></SENT>
<SENT sid="4" pm="."><plain>Pre-treatment as well as post-treatment with TZDs <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> significantly decreased the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and neurological deficits in normotensive, normoglycemic, hypertensive and hyperglycemic rodents </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> neuroprotection was not enhanced by <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> x receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> 9-cis-<z:chebi fb="2" ids="26536">retinoic acid</z:chebi>, but was prevented by PPARgamma <z:chebi fb="68" ids="48706">antagonist</z:chebi> GW9662 </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> significantly decreased the post-ischemic intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 expression and extravasation of macrophages and neutrophils into brain </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> treatment curtailed the post-ischemic expression of the pro-inflammatory genes interleukin-1beta, interleukin-6, macrophage inflammatory protein-1alpha, monocyte chemoattractant protein-1, cyclooxygenase-2, inducible nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase, early growth response-1, CCAAT/enhancer binding protein-beta and nuclear factor-kappa B, and increased the expression of the anti-oxidant enzymes catalase and copper/zinc-<z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> also increased the expression of the anti-inflammatory gene suppressor of cytokine signaling-3 and prevented the phosphorylation of the transcription factor signal transducer and activator of transcription-3 after focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, PPARgamma activation with TZDs might be a potent therapeutic option for preventing <z:mp ids='MP_0001845'>inflammation</z:mp> and neuronal damage after <z:hpo ids='HP_0001297'>stroke</z:hpo> with promise in diabetic and hypertensive subjects </plain></SENT>
</text></document>